Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences.
Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences.
复制标题
DOI：
10.37201/req/054.2022
复制
发表时间：
2022-08
影响因子：
1.9
通讯作者：
Barberan, Jose
中科院分区：
文献类型：
--
作者：
Ramon Azanza, Jose;Mensa, Josep;Gonzalez del Castillo, Juan;Linares Rufo, Manuel;Maria Molero, Jose;Madero Valle, Natalia;Barberan, Jose
Paxlovid （nirmatrelvir + ritonavir）是治疗COVID-19的新型口服抗病毒药物。尼马特利韦是SARS-CoV-2主要蛋白酶的抑制剂，而利托那韦作为低剂量的CYP3A抑制剂，可以减缓尼马特利韦的代谢，从而增强其治疗效果。CYP3A4同工酶至少负责约60%可用药物的部分氧化代谢，因此利托那韦是药物相互作用的重要来源。我们在这里描述了当Paxlovid （nirmaltrevir + ritonavir）应该根据西班牙药品和保健品管理局的每一份有效的情况说明书进行管理时，禁忌症或应该有或没有预防措施使用的药物。
Paxlovid (nirmatrelvir plus ritonavir) is a new oral antiviral therapeutic for the treatment of COVID-19. Nirmatrelvir is an inhibitor of SARS-CoV-2 main protease, while ritonavir is used as a CYP3A inhibitor in low doses to slow the metabolism of nirmatrelvir, thus enhancing their therapeutic effect. The iso-enzyme CYP3A4 is responsible for at least part of the oxidative metabolism of approximately 60% of available medications and ritonavir is therefore a significant source of drug interactions. We describe here the drugs that are contraindicated or should be used with or without precautions when Paxlovid (nirmaltrevir plus ritonavir) should be administered according to each fact sheet in force at the Spanish Agency for Medicines and Health Products.